Medical Device User Fee Rates for Fiscal Year 2025, 61433-61441 [2024-16883]
Download as PDF
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
at OO-OFBAP-OFM-UFFS-Government@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–N–3453]
Medical Device User Fee Rates for
Fiscal Year 2025
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
fee rates and payment procedures for
medical device user fees for fiscal year
(FY) 2025. The Federal Food, Drug, and
Cosmetic Act (FD&C Act), as amended
by the Medical Device User Fee
Amendments of 2022 (MDUFA V),
authorizes FDA to collect user fees for
certain medical device submissions and
annual fees both for certain periodic
reports and for establishments subject to
registration. This notice establishes the
fee rates for FY 2025, which apply from
October 1, 2024, through September 30,
2025, and provides information on how
the fees for FY 2025 were determined,
the payment procedures you should
follow, and how you may qualify for
reduced small business fees.
FOR FURTHER INFORMATION CONTACT:
For information on Medical Device
User Fees: https://www.fda.gov/
industry/fda-user-fee-programs/
medical-device-user-fee-amendmentsmdufa.
For questions relating to the MDUFA
Small Business Program, please visit the
Center for Devices and Radiological
Health’s website: https://www.fda.gov/
medical-devices/premarketsubmissions/reduced-medical-deviceuser-fees-small-business-determinationsbd-program.
For questions relating to this notice:
Olufunmilayo Ariyo, Office of Financial
Management, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20903, 240–
402–4989; or the User Fee Support Staff
SUMMARY:
I. Background
The FD&C Act, as amended by
MDUFA V, authorizes FDA to collect
user fees for certain medical device
submissions and annual fees both for
certain periodic reports and for
establishments subject to registration.
Section 738 of the FD&C Act (21 U.S.C.
379j) establishes fees for certain medical
device applications, submissions,
supplements, notices, and requests (for
simplicity, this document refers to these
collectively as ‘‘submissions’’ or
‘‘applications’’); for periodic reporting
on class III devices; and for the
registration of certain establishments.
Under the FD&C Act, the fee rate for
each type of submission is set at a
specified percentage of the standard fee
for a premarket application (a premarket
application is a premarket approval
application (PMA), a product
development protocol (PDP), or a
biologics license application (BLA)).
The FD&C Act specifies the base fee for
a premarket application for each year
from FY 2023 through FY 2027; the base
fee for a premarket application received
by FDA during FY 2025 is $445,000.
From this starting point, this document
establishes FY 2025 fee rates for certain
types of submissions, and for periodic
reporting, by applying criteria specified
in the FD&C Act. Under statutorily
defined conditions, a qualified
applicant may receive a fee waiver or
may pay a lower small business fee (see
sections 738(a)(3)(B), 738(d) and 738(e)
of the FD&C Act). For more information
on fee waivers, please see Section IX.
Small Business Fee Reductions and Fee
Waivers.
The FD&C Act specifies the base fee
for establishment registration for each
year from FY 2023 through FY 2027; the
base fee for an establishment
registration in FY 2025 is $7,100. Each
establishment that is registered (or is
required to register) with the Secretary
61433
of Health and Human Services under
section 510 of the FD&C Act (21 U.S.C.
360), because such establishment is
engaged in the manufacture,
preparation, propagation, compounding,
or processing of a device, is required to
pay the annual fee for establishment
registration.
II. Total Revenue Amount for FY 2025
The total revenue amount for FY 2025
is $350,746,400, as set forth in the
statute prior to the inflation adjustment
(see section 738(b)(3) of the FD&C Act).
MDUFA V directs FDA to use the yearly
total revenue amount as a starting point
to set the standard fee rates for each fee
type. The fee calculations for FY 2025
are described in this document.
Inflation Adjustment
MDUFA specifies that the
$350,746,400 is to be adjusted for
inflation increases for FY 2025 using
two separate adjustments: one for
payroll costs and one for non-payroll
costs (see section 738(c)(2) of the FD&C
Act). The base inflation adjustment for
FY 2025 is the sum of one plus the two
separate adjustments and is
compounded as specified in the statute
(see section 738(c)(2)(C) and 738(c)(2)(B)
of the FD&C Act).
The component of the inflation
adjustment for payroll costs is the
average annual percent change in the
cost of all personnel compensation and
benefits (PC&B) paid per full-time
equivalent (FTE) position at FDA for the
first 3 of the 4 preceding FYs,
multiplied by 0.60, or 60 percent (see
section 738(c)(2)(C)(i)(I) of the FD&C
Act).
Table 1 summarizes the actual cost
and FTE data for the specified FYs,
provides the percent change from the
previous fiscal year, and provides the
average percent change over the first 3
of the 4 fiscal years preceding FY 2025.
The 3-year average is 3.8539 percent
(rounded).
TABLE 1—FDA PC&BS EACH YEAR AND PERCENT CHANGE
FY 2021
lotter on DSK11XQN23PROD with NOTICES1
Total PC&B ..........................................................................................
Total FTE .............................................................................................
PC&B per FTE .....................................................................................
Percent change from previous year ....................................................
The payroll adjustment is 3.8539
percent multiplied by 60 percent, or
2.3123 percent. The statute specifies
that the component of the inflation
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
$3,039,513,000
18,501
$164,289
0.1811%
FY 2022
$3,165,477,000
18,474
$171,348
4.2967%
adjustment for non-payroll costs for FY
2025 is the average annual percent
change that occurred in the Consumer
Price Index (CPI) for urban consumers
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
FY 2023
$3,436,513,000
18,729
$183,486
7.0838%
3-Year
average
........................
........................
........................
3.8539%
(Washington-Arlington-Alexandria, DCVA-MD-WV; Not Seasonally Adjusted;
All Items; Annual Index) for the first 3
of the preceding 4 years of available
E:\FR\FM\31JYN1.SGM
31JYN1
61434
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
data multiplied by 0.40, or 40 percent
(see section 738(c)(2)(C)(i)(II) of the
FD&C Act).
Table 2 provides the summary data
and the 3-year average percent change
in the specified CPI for the WashingtonArlington-Alexandria area. These data
are published by the Bureau of Labor
Statistics and can be found on their
website under series Id CUURS35ASA0
at: https://data.bls.gov/pdq/
SurveyOutputServlet?data_
tool=dropmap&series_
id=CUURS35ASA0,CUUSS35ASA0.
TABLE 2—ANNUAL AND 3-YEAR AVERAGE PERCENT CHANGE IN WASHINGTON-ARLINGTON-ALEXANDRIA AREA CPI
Annual CPI ...........................................................................................
Annual Percent Change ......................................................................
3-Year Average Percent Change in CPI .............................................
The non-payroll adjustment is 4.5616
percent multiplied by 40 percent, or
1.8246 percent. Next, the payroll
adjustment (2.3123 percent or 0.023123)
is added to the non-payroll adjustment
(1.8246 percent or 0.018246), for a total
of 4.1369 percent (or 0.041369). To
complete the inflation adjustment, 1
(100 percent or 1.0) is added for a total
base inflation adjustment of 1.041369
for FY 2025. If the base inflation
adjustment for a fiscal year is greater
than 1.04, such adjustment shall be
considered to be equal to 1.04 (see
section 738(c)(2)(C)(ii)(II) of the FD&C
Act). The total base inflation adjustment
for FY 2025 is 1.04.
MDUFA V provides for this inflation
adjustment to be compounded for FY
2023 and each subsequent fiscal year
(see section 738(c)(2)(B) of the FD&C
Act). To complete the compounded
inflation adjustment for FY 2025, the FY
2024 compounded adjustment
(1.079318) is multiplied by the FY 2025
base inflation adjustment (1.040000) to
reach the applicable inflation
adjustment of 1.122491 (rounded) for
FY 2025. We then multiply the total
revenue amount for FY 2025
($350,746,400) by 1.122491, yielding an
inflation adjusted total revenue amount
of $393,710,000 (rounded to the nearest
thousand dollars).
III. Adjustments to Base Fee Amounts
for FY 2025
lotter on DSK11XQN23PROD with NOTICES1
Under the FD&C Act, all submission
fees and the periodic reporting fee are
set as a percent of the standard (full) fee
for a premarket application (see section
738(a)(2)(A) and (b)(1) of the FD&C Act).
2021
2022
2023
3-Year
average
277.728
3.9568%
............................
296.117
6.6212%
............................
305.317
3.1069%
............................
........................
........................
4.5616%
1.122491 yields inflation adjusted base
fees of $499,508 (premarket application)
and $7,970 (establishment registration).
B. Further Adjustments To Generate the
Inflation-Adjusted Total Revenue
Amount
After the applicable inflation
adjustment to fees is done, FDA may
increase, if necessary to achieve the
inflation adjusted total revenue amount,
the base fee amounts on a uniform
proportionate basis (see section
738(c)(2)(D)(ii) of the FD&C Act). After
this adjustment, if necessary, FDA may
further increase the base establishment
registration fees to generate the
inflation-adjusted total revenue amount
(see section 738(c)(3) of the FD&C Act).
For FY 2025, further adjustments
were required to meet the inflation
adjusted total revenue amount of
$393,710,000. After increasing base fees,
on a uniform proportionate basis, and
further increasing establishment
registration fees, this yields inflation
adjusted base fees of $540,783
(premarket application) and $8,716
(establishment registration).
C. MDUFA V Adjustments Solely to
Registration Fees
MDUFA V has three new potential
adjustments that will not change the
total revenue amount but may impact
collections by increasing or decreasing
establishment registration base fees
only. These adjustments are the
performance improvement adjustment,
the hiring adjustment, and the operating
reserve adjustment.
A. Inflation Adjustment
1. Performance Improvement
Adjustment
MDUFA specifies that the base fees of
$445,000 (premarket application) and
$7,100 (establishment registration) are
to be adjusted for FY 2025 using the
same methodology as that for the total
revenue inflation adjustment in section
II (see section 738I(2)(D)(i) of the FD&C
Act). Multiplying the base fees by the
compounded inflation adjustment of
Beginning with FY 2025, this
adjustment allows FDA to collect fees in
addition to the total revenue amount in
FYs 2025, 2026, and 2027, if the Agency
meets certain performance goals in FYs
2023, 2024, and 2025. If applicable, this
provision further increases base
establishment registration fee amounts
to achieve an increase in total fee
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
collections equal to the applicable
performance improvement adjustment,
which is set forth in the statute (see
section 738(c)(4) of the FD& C Act). FDA
met the FY 2023 Pre-Submission
Written Feedback goal, which triggers
the performance improvement
adjustment for FY 2025.
For FY 2025, the performance
improvement adjustment is equal to the
product of the pre-submission amount
in section 738(c)(4)(B)(i)(I) of the FD&C
Act, $15,396,600, and the inflation
adjustment under section 738(c)(2)(B) of
the FD&C Act, 1.122491. See section
738(c)(4)(A)(i) of the FD&C Act. For FY
2025, the performance improvement
adjustment is $17,282,545.
2. Hiring Adjustment
Beginning with FY 2025, this
adjustment provides for the reduction of
base establishment registration fees in
FYs 2025, 2026, and 2027, if specified
hiring goals for FYs 2023, 2024, and
2025 are not met by a certain threshold.
The hiring adjustment would serve to
decrease the base establishment
registration fee amounts, as necessary,
to achieve a reduction in total fee
collections equal to the hiring
adjustment amount, which is set forth in
the statute (see section 738(c)(5) of the
FD&C Act).
FDA met the FY 2023 statutory hiring
threshold of 123 hires, so establishment
registration fees will not need to be
lowered by the hiring adjustment
amount in FY 2025. Since FDA met the
FY 2023 Pre-Submission Written
Feedback goal, the FY 2027 statutory
hiring goal will be 83 hires for fiscal
year 2025 (see section
738(c)(5)(D)(iii)(II) of the FD&C Act) and
the threshold will be 75 hires for fiscal
year 2025 (see section
738(c)(5)(B)(iii)(II) of the FD&C Act).
3. Operating Reserve Adjustment
For FYs 2023 to 2027, the operating
reserve adjustment requires FDA to
decrease base establishment registration
fees if the amount of operating reserves
E:\FR\FM\31JYN1.SGM
31JYN1
61435
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
of carryover user fees exceeds the
‘‘designated amount’’, and such
reduction is necessary to provide for not
more than such designated amount of
operating reserves of carryover user fees
(see section 738(c)(6)(A) of the FD&C
Act). In making this calculation for FYs
2023 to 2026, a certain amount is
excluded from the designated amount
and is not subject to the decrease (see
section 738(c)(6)(C) of the FD&C Act).
For FY 2025, this excluded amount is
$77,496,161.
The designated amount is equal to the
sum of 13 weeks of operating reserves
of carryover user fees plus 1 month of
operating reserves, as described in
738(c)(8) (see 738(c)(6)(B) of the FD&C
Act).
To determine the 13-week operating
reserves of carryover user fees amount,
the FY 2025 inflation-adjusted total
revenue amount (from section II),
$393,710,000, is added to the inflationadjusted performance improvement
adjustment amount (from section
III.C.1), $17,282,545, resulting in
$410,992,545. This amount is then
divided by 52, and then multiplied by
13. The 13-week operating reserve
amount for FY 2025 is $102,748,136.
To determine the 1 month of
operating reserves described in section
738(c)(8) of the FD&C Act, the FY 2025
inflation-adjusted total revenue amount
of $393,710,000 is added to the
inflation-adjusted performance
improvement adjustment amount of
$17,282,545, resulting in $410,992,545.
This amount is then divided by 12. The
1 month of operating reserves for FY
2025 is $34,249,379.
For FY 2025, the designated amount
is equal to the 13-week operating
reserve of $102,748,136 plus the 1
month of operating reserves of
$34,249,379, totaling $136,997,515.
To determine the FY 2024 end-of-year
operating reserves of carryover user fees
amount, FDA combined the actual
collections and obligations at the end of
the third quarter (June 2024) and added
the forecasted collections and
obligations for the fourth quarter of FY
2024 to generate a full year estimate for
FY 2024. The estimated end-of-year FY
2024 operating reserves of carryover
user fees is $50,394,972 (Note, this
amount includes the 1-month reserve).
Note that under MDUFA V, for the
purposes of calculating the operating
reserve adjustment, this amount does
not include user fee funds considered
unappropriated ($26,680,243) or
unearned revenue ($62,498,454). In
addition, as noted above, for purposes of
the operating reserve adjustment,
operating reserves of carryover user fees
do not include the estimated
$77,496,161 remaining to spend at the
end of FY 2024 from the total of
$118,000,000 intended to support the
Total Product Life Cycle Advisory
Program Pilot and Third-Party Review
programs.
Because the estimated end-of-year FY
2024 MDUFA operating reserves of
carryover user fees amount totaling
$50,394,972 does not exceed the FY
2025 designated amount of
$136,997,515, FDA will not decrease the
base establishment registration fee
amounts for FY 2025 to provide for not
more than such designated amount.
As there is a performance
improvement adjustment for FY 2025,
but no hiring adjustment or operating
reserve adjustment, establishment
registration fees are increased to achieve
an increase in total fee collections for
FY 2025 equal to the performance
improvement adjustment amount of
$17,282,545. After so increasing
establishment registration fees only, this
yields fees of $540,783 (premarket
application) and $9,280 (establishment
registration).
IV. Calculation of Fee Rates
As noted in section II, the total
revenue amount after the applicable
inflation adjustment is $393,710,000
(rounded to the nearest thousand
dollar). As noted in section III, the
performance improvement adjustment
solely to registration fees for FY 2025 is
$17,282,545. There is no hiring
adjustment or operating reserve
adjustment for FY 2025.
Table 3A provides fee-paying
submission counts, excluding
establishment registration, for the last 3
years and the 3-year average. Table 3B
provides establishment registration feepaying submission counts for the most
recently completed fiscal year (FY
2023). Historically, FDA has estimated
the total number of fee-paying
submission counts it expects to receive
during the next fiscal year by averaging
the number of fee-paying submission
counts received in the 3 most recently
completed fiscal years; for FY 2025 feesetting, this would be an average of FY
2021 through FY 2023. FDA received an
abnormally high volume of fee-paying
establishment registrations due to the
COVID–19 pandemic in FY 2020 and FY
2021. The surge in fee-paying
establishment registrations has been
declining starting in FY 2022, trending
back toward pre-pandemic levels. In an
effort to normalize the projected volume
of establishment registration
submissions for the FY 2025 fee-setting
calculation, and more accurately project
the associated establishment registration
revenue, FDA decided to utilize the
number of establishment registration
fee-paying submission counts from FY
2023.
TABLE 3A—THREE-YEAR AVERAGE OF FEE-PAYING SUBMISSIONS
[Excluding establishment registration]
FY 2021
actual
lotter on DSK11XQN23PROD with NOTICES1
Application type
Full Fee applications ........................................................................................
Small Business .........................................................................................
Panel-Track Supplements ...............................................................................
Small Business .........................................................................................
De Novo Classifications ...................................................................................
Small Business .........................................................................................
180-Day Supplements .....................................................................................
Small Business .........................................................................................
Real-Time Supplements ..................................................................................
Small Business .........................................................................................
510(k)s .............................................................................................................
Small Business .........................................................................................
30-Day Notice (Note also includes counts for 135 Day Supplements) ...........
Small Business .........................................................................................
513(g)(21 U.S.C. 360c(g)) Request for Classification Information ..................
Small Business .........................................................................................
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
FY 2022
actual
25
5
31
6
16
42
98
34
150
20
2,133
1,846
843
77
83
53
E:\FR\FM\31JYN1.SGM
18
3
21
1
23
53
93
31
140
12
2,012
1,757
782
67
93
58
31JYN1
FY 2023
actual
31
3
22
5
26
68
113
12
138
28
1,943
2,031
825
53
82
59
3 Yr
average
25
4
25
4
22
54
101
26
143
20
2,029
1,878
817
66
86
57
61436
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
TABLE 3A—THREE-YEAR AVERAGE OF FEE-PAYING SUBMISSIONS—Continued
[Excluding establishment registration]
FY 2021
actual
Application type
Annual Fee for Periodic Reporting ..................................................................
Small Business .........................................................................................
FY 2022
actual
613
84
FY 2023
actual
620
87
3 Yr
average
657
22
630
64
TABLE 3B—FISCAL YEAR 2023 ACTUAL FEE-PAYING ESTABLISHMENT REGISTRATION SUBMISSIONS
Application type
FY 2023
FY 2025 estimate
for registrations
Establishment Registrations ........................................................................................................................
30,645
30,645
The information in tables 3A and 3B
is necessary to estimate the amount of
revenue that will be collected based on
the fee amounts. Tables 4A and 4B
display the FY 2025 base fees set in
statute (column one) and the inflation
adjusted base fees (per calculations in
section III.A.) (column two). Using the
inflation adjusted fees, the 3-year
average of fee-paying submissions
(excluding establishment registration),
and the fee-paying establishment
registration submissions from FY 2023,
collections are projected to total
$361,177,583 which is $32,532,417
lower than the inflation adjusted total
revenue amount (in section II).
Accordingly, the next step in the fee
setting process is to increase the base fee
amounts on a uniform proportionate
basis to generate the inflation adjusted
total revenue amounts (see
738(c)(2)(D)(ii) of the FD&C Act and
table 4A, column three).
Applying these further adjusted fee
rates to the 3-year average of fee-paying
submissions, and the fee-paying
establishment registration submissions
from FY 2023 results in estimated total
fee collections of $391,014,947 which is
still $2,695,053 lower than the inflation
adjusted total revenue amount (in
Section II). The next step in the fee
setting process, after the adjustment in
(2)(D) is done, is to increase the base
establishment registration fee amount as
necessary for total fee collections to
generate the inflation adjusted total
revenue amount, as adjusted under
paragraph (2) (see 738(c)(3) of the FD&C
Act). Accordingly, the base
establishment registration fee was
increased by $88 for an establishment
registration fee rate of $8,716 (see
738(c)(3) of the FD& C Act and table 4B,
column three). The performance
improvement adjustment amount is
$17,282,544. Per statute, the
establishment registration fee is further
adjusted to account for the performance
improvement adjustment amount. The
inflation adjusted establishment
registration fee is increased by $564 for
an establishment registration fee of
$9,280. The fees in column three in
table 4A and column four in table 4B are
those we are establishing for FY 2025,
which are the standard fees.
TABLE 4A—FEES NEEDED TO ACHIEVE NEW FY 2025 REVENUE TARGET
FY 2025
statutory
fees
(base fees)
Application type
lotter on DSK11XQN23PROD with NOTICES1
Full Fee Applications .............................................................................................
Small Business ..............................................................................................
Panel-Track Supplement .......................................................................................
Small Business ..............................................................................................
De Novo Classification Request ...........................................................................
Small Business ..............................................................................................
180-Day Supplements ...........................................................................................
Small Business ..............................................................................................
Real-Time Supplements ........................................................................................
Small Business ..............................................................................................
510(k)s ..................................................................................................................
Small Business ..............................................................................................
30-Day Notice .......................................................................................................
Small Business ..............................................................................................
513(g) Request for Classification Information ......................................................
Small Business ..............................................................................................
Annual Fee for Periodic Reporting .......................................................................
Small Business ..............................................................................................
$445,000
111,250
356,000
89,000
133,500
33,375
66,750
16,688
31,150
7,788
20,025
5,006
7,120
3,560
6,008
3,004
15,575
3,894
FY 2025
inflation
adjusted
statutory
base fees
Adjusted
FY 2025
fees to meet
revenue target
(uniform
proportionate
increase)
$499,508
124,877
399,607
99,902
149,583
37,463
74,926
18,732
34,966
8,741
22,478
5,619
7,992
3,996
6,743
3,372
17,483
4,371
$540,783
135,196
432,626
108,157
162,235
40,559
81,117
20,279
37,855
9,464
24,335
6,084
8,653
4,326
7,301
3,650
18,927
4,732
Total ........................................................................................................
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
PO 00000
Frm 00040
Fmt 4703
3-Year
average of
fee-paying
submissions
25
4
25
4
22
54
101
26
143
20
2,029
1,878
817
66
86
57
630
64
FY 2025
revenue from
adjusted fees
$13,519,575
540,784
10,815,650
432,628
3,569,170
2,190,186
8,192,817
527,254
5,413,265
189,280
49,375,715
11,425,752
7,069,501
285,516
627,886
208,050
11,924,010
302,848
126,609,887
Sfmt 4703
E:\FR\FM\31JYN1.SGM
31JYN1
61437
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
TABLE 4B—FEES NEEDED TO ACHIEVE NEW FY 2025 REVENUE TARGET PLUS/MINUS ADJUSTMENTS
Application type
FY 2025
statutory
fees
(base fees)
FY 2025
inflation
adjusted
statutory
base fees
Adjusted FY 2025
fees to meet
inflation adjusted
total revenue
amount
(uniform proportionate
increase + further
adjustment to
establishment
registrations)
Establishment Registrations ..........................................
$7,100
$7,970
$8,716
The standard fee (adjusted base
amount) for a premarket application,
including a BLA, and for a premarket
report and a BLA efficacy supplement,
is $540,783 for FY 2025. The fees set by
reference to the standard fee for a
premarket application are:
• For a panel-track supplement, 80
percent of the standard fee
• For a de novo classification request,
30 percent of the standard fee
• For a 180-day supplement, 15 percent
of the standard fee
• For a real-time supplement, 7 percent
of the standard fee
• For an annual fee for periodic
reporting concerning a class III
device, 3.5 percent of the standard fee
• For a 510(k) premarket notification,
4.5 percent of the standard fee
• For a 30-day notice, 1.6 percent of the
standard fee
• For a 513(g) request for classification
information, 1.35 percent of the
standard fee
For all submissions other than a 30day notice and a 513(g) request for
classification information, the small
business fee is 25 percent of the
standard (full) fee for the submission
(see section 738(d)(2)(C) and (e)(2)(C) of
the FD&C Act). For a 30-day notice and
Adjusted FY
2025 fees to
meet inflation
adjusted total
revenue +/¥
adjustments
FY 2023
fee-paying
submissions
FY 2025
revenue from
adjusted fees
$9,280
30,645
$267,101,820
a 513(g) request for classification
information, the small business fee is 50
percent of the standard (full) fee for the
submission (see section 738(d)(2)(C) of
the FD&C Act).
The annual fee for establishment
registration, after adjustments, is set at
$9,280 for FY 2025. For FY 2025, there
is no small business waiver for the
annual establishment registration fee; all
establishments pay the same fee.
For more information on reduced fees
and waivers for small businesses, please
see Section IX. Small Business Fee
Reductions and Fee Waivers.
Table 5 summarizes the FY 2025 rates
for all medical device fees.
TABLE 5—MEDICAL DEVICE FEES FOR FY 2025
Standard fee
(as a percent of the standard
fee for a premarket application)
Application fee type
Premarket application (a PMA submitted under section 515(c)(1) of the FD&C Act (21 U.S.C.
360e(c)(1)), a PDP submitted under section 515(f) of the FD&C Act, or a BLA submitted
under section 351 of the Public Health Service Act (the PHS Act) (42 U.S.C. 262)).
Premarket report (submitted under section 515(c)(2) of the FD&C Act) ........................................
Efficacy supplement (to an approved BLA under section 351 of the PHS Act) .............................
Panel-track supplement ...................................................................................................................
De novo classification request .........................................................................................................
180-day supplement ........................................................................................................................
Real-time supplement ......................................................................................................................
510(k) premarket notification submission ........................................................................................
30-day notice ...................................................................................................................................
513(g) request for classification information ...................................................................................
Annual Fee Type .............................................................................................................................
Annual fee for periodic reporting on a class III device ...................................................................
Annual establishment registration fee (to be paid by the establishment engaged in the manufacture, preparation, propagation, compounding, or processing of a device, as defined by 21
U.S.C. 379i(14)).
lotter on DSK11XQN23PROD with NOTICES1
V. How To Qualify as a Small Business
for Purposes of Medical Device Fees
If your business, including your
affiliates, has gross receipts or sales of
no more than $100 million for the most
recent tax year, you may qualify for
reduced small business fees. If your
business, including your affiliates, has
gross sales or receipts of no more than
$30 million, you may also qualify for a
waiver of the fee for your first premarket
application (i.e., PMA, PDP, or BLA) or
premarket report. If you want to pay the
small business fee rate for a submission
or you want to receive a waiver of the
fee for your first premarket application
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
Frm 00041
Fmt 4703
Sfmt 4703
FY 2025 small
business fee
Base fee specified in statute ....
$540,783
$135,196
100% .........................................
100% .........................................
80% ...........................................
30% ...........................................
15% ...........................................
7% .............................................
4.5% ..........................................
1.60% ........................................
1.35% ........................................
...................................................
3.50% ........................................
Base fee specified in statute ....
540,783
540,783
432,626
162,235
81,117
37,855
24,335
8,653
7,301
........................
18,927
9,280
135,196
135,196
108,157
40,559
20,279
9,464
6,084
4,326
3,650
..........................
4,732
9,280
or premarket report, you must submit
the materials showing you qualify as a
small business at least 60 days before
you send your submission to FDA. For
more information on fee waivers or
reductions, please see Section IX. Small
Business Fee Reductions and Fee
Waivers.
Please note that the establishment
registration fee is not eligible for a
reduced small business fee. For FY
2025, there is no small business waiver
for the annual establishment registration
fee. As a result, if the establishment
registration fee is the only medical
device user fee that you will pay in FY
2025, you should not submit a Small
PO 00000
FY 2025
standard fee
Business Certification Request. FDA
will review your information and
determine whether you qualify as a
small business eligible for the reduced
fee and/or fee waiver. If you make a
submission before FDA finds that you
qualify as a small business, you must
pay the standard (full) fee for that
submission.
If your business qualified as a small
business for FY 2024, your status as a
small business will expire at the close
of business on September 30, 2024. You
must re-qualify for FY 2025 in order to
pay small business fees during FY 2025.
E:\FR\FM\31JYN1.SGM
31JYN1
61438
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
lotter on DSK11XQN23PROD with NOTICES1
A. Domestic (U.S.) Businesses
If you are a domestic (U.S.) business
and wish to qualify as a small business
for FY 2025, submit the following to
FDA:
1. A completed MDUFA Small
Business Certification Request for a
Business Headquartered in the United
States (Form FDA 3602). Form FDA
3602 is provided in the FDA Forms
database: https://www.fda.gov/aboutfda/reports-manuals-forms/forms.
2. A signed copy of your Federal
(U.S.) Income Tax Return for the most
recent tax year. The most recent tax year
will be 2024, except:
• If you submit your MDUFA Small
Business Certification Request for FY
2025 before April 15, 2025, and you
have not yet filed your return for 2024,
you may use tax year 2023.
• If you submit your MDUFA Small
Business Certification Request for FY
2025 on or after April 15, 2025, and
have not yet filed your 2024 return
because you obtained an extension, you
may submit your most recent return
filed prior to the extension.
3. For each of your affiliates, either:
• If the affiliate is a domestic (U.S.)
business, a signed copy of the affiliate’s
Federal (U.S.) Income Tax Return for the
most recent tax year, or
• If the affiliate is a foreign business
and cannot submit a Federal (U.S.)
Income Tax Return, a National Taxing
Authority Certification completed by,
and bearing the official seal of, the
National Taxing Authority, if extant, of
the country in which the firm is
headquartered. The National Taxing
Authority is the foreign equivalent of
the U.S. Internal Revenue Service. This
certification must show the amount of
gross receipts or sales for the most
recent tax year, in both U.S. dollars and
the local currency of the country, the
exchange rate used in converting the
local currency to U.S. dollars, and the
dates of the gross receipts or sales
collected. The business must also
submit a statement signed by the head
of the business’s firm or by its chief
financial officer that the business has
submitted certifications for all of its
affiliates, identifying the name of each
affiliate, or that the business has no
affiliates.
• If your affiliate is headquartered in
a country without a National Taxing
Authority, please contact the Division of
Industry and Consumer Education at
800–638–2041 or 301–796–7100 or
email at DICE@fda.hhs.gov.
4. Once you have completed and
signed your Form FDA 3602, submit
your form and your supporting
documentation (copies of the Federal
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
(U.S.) income tax returns), using the
instructions which are available at the
following website: https://www.fda.gov/
MedicalDevices/
DeviceRegulationandGuidance/
HowtoMarketYourDevice/
PremarketSubmissions/ucm577696.htm.
If you need assistance, please contact
the Division of Industry and Consumer
Education at 800–638–2041 or 301–796–
7100 or email at DICE@fda.hhs.gov.
B. Foreign Businesses
If you are a foreign business, and wish
to qualify as a small business for FY
2025, submit the following:
1. A completed MDUFA Foreign
Small Business Certification Request for
a Business Headquartered Outside the
United States (Form FDA 3602A). Form
FDA 3602A is provided in the FDA
Forms database: https://www.fda.gov/
about-fda/reports-manuals-forms/forms.
2. A National Taxing Authority
Certification, completed by, and bearing
the official seal of, the National Taxing
Authority, if extant, of the country in
which the firm is headquartered. This
certification must show the amount of
gross receipts or sales for the most
recent tax year, in both U.S. dollars and
the local currency of the country, the
exchange rate used in converting the
local currency to U.S. dollars, and the
dates of the gross receipts or sales
collected.
If your firm is headquartered in a
country without a National Taxing
Authority, please contact the Division of
Industry and Consumer Education at
800–638–2041 or 301–796–7100 or
email at DICE@fda.hhs.gov.
3. For each of your affiliates, either:
• If the affiliate is a domestic (U.S.)
business, a signed copy of the affiliate’s
Federal (U.S.) Income Tax Return for the
most recent tax year (2023 or later), or
• If the affiliate is a foreign business
and cannot submit a Federal (U.S.)
Income Tax Return, a National Taxing
Authority Certification completed by,
and bearing the official seal of, the
National Taxing Authority, if extant, of
the country in which the firm is
headquartered. The National Taxing
Authority is the foreign equivalent of
the U.S. Internal Revenue Service. This
certification must show the amount of
gross receipts or sales for the most
recent tax year, in both U.S. dollars and
the local currency of the country, the
exchange rate used in converting the
local currency to U.S. dollars, and the
dates for the gross receipts or sales
collected. The business must also
submit a statement signed by the head
of the business’s firm or by its chief
financial officer that the applicant has
submitted certifications for all of its
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
affiliates, identifying the name of each
affiliate, or that the business has no
affiliates.
• If your affiliate is headquartered in
a country without a National Taxing
Authority, please contact the Division of
Industry and Consumer Education at
800–638–2041 or 301–796–7100 or
email at DICE@fda.hhs.gov.
4. Once you have completed and
signed your Form FDA 3602A, submit
your form and your supporting
documentation, including the following,
using the instructions which are
available at the following website:
https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
HowtoMarketYourDevice/
PremarketSubmissions/ucm577696.htm.
• A copy of the most recent Federal
(U.S.) income tax return for each of your
affiliates headquartered in the U.S. and
• A copy of an MDUFA Foreign Small
Business Certification Request for each
of your foreign affiliates.
If you need assistance, please contact
the Division of Industry and Consumer
Education at 800–638–2041 or 301–796–
7100 or email at DICE@fda.hhs.gov.
VI. Procedures for Paying Application
Fees
If your application or submission is
subject to a fee and your payment is
received by FDA between October 1,
2024, and September 30, 2025, you must
pay the fee in effect for FY 2025. To
avoid delay in the review of your
application, you should pay the
application fee at the time you submit
your application to FDA. The later of
the date that the application is received
in the reviewing center’s document
room or the date the U.S. Treasury
recognizes the payment determines
whether the fee rates for FY 2024 or FY
2025 apply. FDA must receive the
correct fee at the time that an
application is submitted, or the
application will not be accepted for
filing or review.
FDA requests that you follow the
steps below before submitting a medical
device application subject to a fee to
ensure that FDA links the fee with the
correct application. (Note: Do not send
your user fee check to FDA with the
application.)
A. Secure a Payment Identification
Number (PIN) and Medical Device User
Fee Cover Sheet From FDA Before
Submitting Either the Application or the
Payment
Log into the User Fee System at:
https://userfees.fda.gov/OA_HTML/
mdufmaCAcdLogin.jsp. Complete the
Medical Device User Fee cover sheet. Be
sure you choose the correct application
E:\FR\FM\31JYN1.SGM
31JYN1
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
submission date range. (Two choices
will be offered until October 1, 2024.
One choice is for applications and fees
that will be received on or before
September 30, 2024, which are subject
to FY 2024 fee rates. A second choice
is for applications and fees received on
or after October 1, 2024, which are
subject to FY 2025 fee rates.) After
completing data entry, print a copy of
the Medical Device User Fee cover sheet
and note the unique PIN located in the
upper right-hand corner of the printed
cover sheet.
B. Electronically Transmit a Copy of the
Printed Cover Sheet With the PIN
When you are satisfied that the data
on the cover sheet is accurate,
electronically transmit that data to FDA
according to instructions on the screen.
Applicants are required to set up a user
account and password to assure data
security in the creation and electronic
submission of cover sheets.
lotter on DSK11XQN23PROD with NOTICES1
C. Submit Payment for the Completed
Medical Device User Fee Cover Sheet
1. The preferred payment method is
online using electronic check
(Automated Clearing House (ACH) also
known as eCheck) or credit card
(Discover, VISA, MasterCard, American
Express). FDA has partnered with the
U.S. Department of the Treasury to
utilize Pay.gov, a web-based payment
system, for online electronic payment.
You may make a payment via electronic
check or credit card after submitting
your cover sheet. Secure electronic
payments can be submitted using the
User Fees Payment Portal at https://
userfees.fda.gov/pay. Note: Only full
payments are accepted. No partial
payments can be made online. Once you
search for your invoice, select ‘‘Pay
Now’’ to be redirected to Pay.gov.
Electronic payment options are based on
the balance due. Payment by credit card
is available for balances that are less
than $25,000. If the balance exceeds this
amount, only the ACH option is
available. Payments must be made using
U.S bank accounts as well as U.S. credit
cards.
2. If paying with a paper check:
• All paper checks must be in U.S.
currency from a U.S. bank and made
payable to the Food and Drug
Administration. If needed, FDA’s tax
identification number is 53–0196965.
• Please write your application’s
unique PIN (from the upper right-hand
corner of your completed Medical
Device User Fee cover sheet) on your
check.
• Mail the paper check and a copy of
the completed cover sheet to: Food and
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
Drug Administration, P.O. Box 979033,
St. Louis, MO 63197–9000.
If you prefer to send a check by a
courier, the courier may deliver the
check to: U.S. Bank, Attn: Government
Lockbox 979033, 3180 Rider Trail S,
Earth City, MO 63045. (Note: This U.S.
Bank address is for courier delivery
only. If you have any questions
concerning courier delivery contact U.S.
Bank at 800–495–4981. This telephone
number is only for questions about
courier delivery).
3. If paying with a wire transfer:
• Please include your application’s
unique PIN (from the upper right-hand
corner of your completed Medical
Device User Fee cover sheet) in your
wire transfer. Without the PIN, your
payment may not be applied to your
cover sheet and review of your
application may be delayed.
• The originating financial institution
may charge a wire transfer fee. If the
financial institution charges a wire
transfer fee it is required that you add
that amount to the payment to ensure
that the invoice is paid in full.
Use the following account
information when sending a wire
transfer: U.S. Department of the
Treasury, TREAS NYC, 33 Liberty St.,
New York, NY 10045, Acct. No.
75060099, Routing No. 021030004,
SWIFT: FRNYUS33.
FDA records the official application
receipt date as the later of the following:
(1) the date the application was received
by the FDA Document Control Center
for the reviewing Center or (2) the date
the U.S. Treasury recognizes the
payment.
D. Submit Your Application to FDA
With a Copy of the Completed Medical
Device User Fee Cover Sheet
Please submit your application and a
copy of the completed Medical Device
User Fee cover sheet to the address
located at https://www.fda.gov/
cdrhsubmissionaddress.
VII. Procedures for Paying the Annual
Fee for Periodic Reporting
You will be invoiced at the end of the
quarter in which your PMA Periodic
Report is due. Invoices will be sent
based on the details included on your
PMA file. You are responsible for
ensuring FDA has your current billing
information, and you may update your
contact information for the PMA by
submitting an amendment to the
pending PMA or a supplement to the
approved PMA.
1. The preferred payment method is
online using electronic check (ACH also
known as eCheck) or credit card
(Discover, VISA, MasterCard, American
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
61439
Express). Secure electronic payments
can be submitted using the User Fees
Payment Portal at https://
userfees.fda.gov/pay (Note: Only full
payments are accepted. No partial
payments can be made online). Once
you search for your invoice, select ‘‘Pay
Now’’ to be redirected to Pay.gov. Note
that electronic payment options are
based on the balance due. Payment by
credit card is available for balances that
are less than $25,000. If the balance
exceeds this amount, only the ACH
option is available. Payments must be
made using U.S. bank accounts as well
as U.S. credit cards.
2. If paying with a paper check: The
check must be in U.S. currency from a
U.S. bank and made payable to the Food
and Drug Administration. If needed,
FDA’s tax identification number is 53–
0196965.
• Please write your invoice number
on the check.
• Mail the paper check and a copy of
the invoice to: Food and Drug
Administration, P.O. Box 979033, St.
Louis, MO 63197–9000.
To send a check by a courier, the
courier must deliver the check and
printed copy of the cover sheet to U.S.
Bank, Attn: Government Lockbox
979033, 3180 Rider Trail S, Earth City,
MO 63045. (Note: This U.S. Bank
address is for courier delivery only. If
you have any questions concerning
courier delivery, contact U.S. Bank at
800–495–4981. This telephone number
is only for questions about courier
delivery).
3. When paying by a wire transfer, it
is required that the invoice number is
included; without the invoice number
the payment may not be applied. If the
payment amount is not applied, the
invoice amount would be referred to
collections. The originating financial
institution may charge a wire transfer
fee. If the financial institution charges a
wire transfer fee, it is required that you
add that amount to the payment to
ensure that the invoice is paid in full.
Use the following account
information when sending a wire
transfer: U.S. Department of the
Treasury, TREAS NYC, 33 Liberty St.,
New York, NY 10045, Acct. No.
75060099, Routing No. 021030004,
SWIFT: FRNYUS33.
VIII. Procedures for Paying Annual
Establishment Registration Fees
To pay the annual establishment
registration fee, firms must access the
Device Facility User Fee (DFUF) website
at https://userfees.fda.gov/OA_HTML/
furls.jsp. (FDA has verified the website
address, but FDA is not responsible for
any subsequent changes to the website
E:\FR\FM\31JYN1.SGM
31JYN1
61440
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
address after this document publishes in
the Federal Register.) Create a DFUF
order and you will be issued a PIN
when you place your order. After
payment has been processed, you will
be issued a payment confirmation
number (PCN). You will not be able to
register your establishment if you do not
have a PIN and a PCN. An establishment
required to pay an annual establishment
registration fee is not legally registered
in FY 2025 until it has completed the
steps below to register and pay any
applicable fee (see section 738(f)(2) of
the FD&C Act).
Companies that do not manufacture
any product other than a licensed
biologic are required to register in the
Blood Establishment Registration (BER)
system. FDA’s Center for Biologics
Evaluation and Research (CBER) will
send establishment registration fee
invoices annually to these companies.
lotter on DSK11XQN23PROD with NOTICES1
A. Submit a DFUF Order With a PIN
From FDA Before Registering or
Submitting Payment
To submit a DFUF Order, you must
create or have previously created a user
account and password for the user fee
website listed previously in this section.
After creating a username and
password, log into the Establishment
Registration User Fee FY 2025 store.
Complete the DFUF order by entering
the number of establishments you are
registering that require payment. When
you are satisfied that the information in
the order is accurate, electronically
transmit that data to FDA according to
instructions on the screen. Print a copy
of the final DFUF order and note the
unique PIN located in the upper righthand corner of the printed order.
B. Pay for Your DFUF Order
Unless paying by U.S. credit card, all
payments must be in U.S. currency and
drawn on a U.S. bank.
1. If paying by credit card or
electronic check (ACH or eCheck): The
DFUF order will include payment
information, including details on how
you can pay online using a credit card
or electronic check. Follow the
instructions provided to make an
electronic payment.
2. If paying with a paper check: The
check must be in U.S. currency and
drawn on a U.S. bank, and mailed to:
Food and Drug Administration, P.O.
Box 979033, St. Louis, MO 63197–9000.
If a check is sent by a courier that
requests a street address, the courier can
deliver the check to: U.S. Bank, Attn:
Government Lockbox 979033, 3180
Rider Trail S, Earth City, MO 63045.
(Note: This U.S. Bank address is for
courier delivery only. If you have any
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
questions concerning courier delivery,
contact U.S. Bank at 800–495–4981.
This telephone number is only for
questions about courier delivery.)
Please make sure that both of the
following are written on your check: (1)
the FDA post office box number (P.O.
Box 979033) and (2) the PIN that is
printed on your order. Include a copy of
your printed order when you mail your
check.
3. If paying with a wire transfer: Wire
transfers may also be used to pay annual
establishment registration fees. To send
a wire transfer, please read and comply
with the following information:
Include your order’s unique PIN (in
the upper right-hand corner of your
completed DFUF order) in your wire
transfer. Without the PIN, your payment
may not be applied to your facility and
your registration may be delayed.
The originating financial institution
may charge a wire transfer fee. If the
financial institution charges a wire
transfer fee, it is required that you add
that amount to the payment to ensure
that the invoice is paid in full. Use the
following account information when
sending a wire transfer: U.S. Dept. of the
Treasury, TREAS NYC, 33 Liberty St.,
New York, NY 10045, Acct. No.
75060099, Routing No. 021030004,
SWIFT: FRNYUS33. If needed, FDA’s
tax identification number is 53–
0196965.
C. Complete the Information Online To
Update Your Establishment’s Annual
Registration for FY 2025, or To Register
a New Establishment for FY 2025
Go to the Center for Devices and
Radiological Health’s website at https://
www.fda.gov/medical-devices/howstudy-and-market-your-device/deviceregistration-and-listing and click the
‘‘Access Electronic Registration’’ link on
the left side of the page. This opens a
new page with important information
about the FDA Unified Registration and
Listing System (FURLS). After reading
this information, click on the ‘‘Access
Electronic Registration’’ link in the
middle of the page. This link takes you
to an FDA Industry Systems page with
tutorials that demonstrate how to create
a new FURLS user account if your
establishment did not create an account
in FY 2024. Manufacturers of licensed
biologics should register in the
electronic Blood Establishment
Registration (eBER) system at https://
www.fda.gov/vaccines-blood-biologics/
guidance-compliance-regulatoryinformation-biologics/biologicsestablishment-registration.
Enter your existing account ID and
password to log into FURLS. From the
FURLS/FDA Industry Systems menu,
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
click on the Device Registration and
Listing Module (DRLM) of FURLS
button. New establishments will need to
register, and existing establishments
will update their annual registration
using choices on the DRLM menu.
When you choose to register or update
your annual registration, the system will
prompt you through the entry of
information about your establishment
and your devices. If you have any
problems with this process, email:
reglist@cdrh.fda.gov or call 301–796–
7400 for assistance. (Note: This email
address and this telephone number are
for assistance with establishment
registration only; they are not to be used
for questions related to other aspects of
medical device user fees.) Problems
with the eBER system should be
directed to https://
www.accessdata.fda.gov/scripts/email/
cber/bldregcontact.cfm or call 240–402–
8360.
D. Enter Your DFUF Order PIN and PCN
After completing your annual or
initial registration and device listing,
you will be prompted to enter your
DFUF order PIN and PCN, when
applicable. This process does not apply
to establishments engaged only in the
manufacture, preparation, propagation,
compounding, or processing of licensed
biologic devices. CBER will send
invoices for payment of the
establishment registration fee to such
establishments.
IX. Small Business Fee Reductions and
Fee Waivers
To qualify for reduced fees for small
businesses or a small business fee
waiver, please see the requirements for
qualification provided in Section V.
How To Qualify as a Small Business for
Purposes of Medical Device Fees. The
applicant should submit a Small
Business Certification Request and the
supporting materials showing you
qualify as a small business at least 60
days before you send your submission
to FDA. FDA will review your
information and determine whether you
qualify as a small business eligible for
the reduced fee and/or fee waiver. If you
make a submission before FDA finds
that you qualify as a small business, you
must pay the standard (full) fee for that
submission.
If you need assistance, please contact
the Division of Industry and Consumer
Education at 800–638–2041 or 301–796–
7100 or email at DICE@fda.hhs.gov.
A. Premarket Approval Fee Reduction
or Waiver
A small business applicant may
request to pay a reduced rate for
E:\FR\FM\31JYN1.SGM
31JYN1
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
premarket approval fees. An applicant
may also request a fee waiver for their
first premarket application or premarket
report (section 738(d) of the FD&C Act).
B. Premarket Notification Submission
Fee Reduction
A small business applicant may
request to pay a reduced rate for a
premarket notification submission.
C. Annual Establishment Registration
Fee Waiver
For FY 2025, there is no small
business waiver for the annual
establishment registration fee; all
establishments pay the same fee.
X. Refunds
To qualify for consideration for a
refund, a person shall submit to FDA a
written request for a refund not later
than 180 days after such fee is due. FDA
has discretion to refund a fee or a
portion of the fee. A determination by
FDA concerning a refund shall not be
reviewable. For more information on
qualifying and submitting a refund, see
section 738(a)(2)(D) of the FD&C Act.
Dated: July 26, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–16883 Filed 7–30–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–N–3423]
Biosimilar User Fee Rates for Fiscal
Year 2025
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing the rates for biosimilar user
fees for fiscal year (FY) 2025. The
Federal Food, Drug, and Cosmetic Act
(FD&C Act), as amended by the
Biosimilar User Fee Amendments of
2022 (BsUFA III), authorizes FDA to
assess and collect user fees for certain
activities in connection with biosimilar
biological product development; review
of certain applications for approval of
biosimilar biological products; and each
biosimilar biological product approved
in a biosimilar biological product
application. BsUFA III directs FDA to
establish, before the beginning of each
fiscal year, the amount of initial and
annual biosimilar biological product
development (BPD) fees, the
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
reactivation fee, and the biosimilar
biological product application and
program fees for such year. These fees
apply to the period from October 1,
2024, through September 30, 2025.
FOR FURTHER INFORMATION CONTACT:
Olufunmilayo Ariyo, Office of Financial
Management, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993, 240–
402–4989, and the User Fees Support
Staff at OO-OFBAP-OFM-UFSSGovernment@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Sections 744G, 744H, and 744I of the
FD&C Act (21 U.S.C. 379j–51, 379j–52,
and 379j–53), as amended by BsUFA III,
authorize the collection of fees for
biosimilar biological products. Under
section 744H(a)(1)(A) of the FD&C Act,
the initial BPD fee for a product is due
when the sponsor submits an
investigational new drug (IND)
application that FDA determines is
intended to support a biosimilar
biological product application or within
7 calendar days after FDA grants the
first BPD meeting, whichever occurs
first. A sponsor who has paid the initial
BPD fee is considered to be participating
in FDA’s BPD program for that product.
Under section 744H(a)(1)(B) of the
FD&C Act, once a sponsor has paid the
initial BPD fee for a product, the annual
BPD fee is assessed beginning with the
next fiscal year. The annual BPD fee is
assessed for the product each fiscal year
until the sponsor submits a marketing
application for the product that is
accepted for filing, the sponsor
discontinues participation in FDA’s
BPD program for the product, or the
sponsor has been administratively
removed from the BPD program for the
product.
Under section 744H(a)(1)(D) of the
FD&C Act, if a sponsor has discontinued
participation in FDA’s BPD program or
has been administratively removed from
the BPD program for a product and
wants to reengage with FDA on
development of the product, the sponsor
must pay all annual BPD fees previously
assessed for such product and still
owed, and a reactivation fee to resume
participation in the program. The
sponsor must pay the reactivation fee by
the earlier of the following dates: (1) no
later than 7 calendar days after FDA
grants the sponsor’s request for a BPD
meeting for that product or (2) upon the
date of submission by the sponsor of an
IND describing an investigation that
FDA determines is intended to support
a biosimilar biological product
application for that product. The
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
61441
sponsor will be assessed an annual BPD
fee beginning in the next fiscal year after
payment of the reactivation fee.
BsUFA III also authorizes fees for
certain biosimilar biological product
applications and for each biosimilar
biological product identified in an
approved biosimilar biological product
application (section 744H(a)(2) and (3)
of the FD&C Act). Under certain
conditions, FDA will grant a small
business a waiver of the biosimilar
biological product application fee
(section 744H(d)(1) of the FD&C Act).
For FY 2023 through FY 2027, the
base revenue amounts for the total
revenues from all BsUFA fees are
established by BsUFA III. For FY 2025,
the base revenue amount is the FY 2024
total revenue amount excluding any
operating reserve adjustment, which
equates to the amount of $51,058,823.
The FY 2025 base revenue amount is to
be adjusted by the inflation adjustment,
strategic hiring and retention
adjustment, capacity planning
adjustment (CPA), operating reserve
adjustment, and the additional dollar
amount. Each of these adjustments will
be discussed in the sections below.
This document provides fee rates for
FY 2025 for the initial and annual BPD
fee ($10,000), for the reactivation fee
($20,000), for an application requiring
clinical data ($1,471,118) for an
application not requiring clinical data
($735,559) and for the program fee
($256,168). These fees are effective on
October 1, 2024, and will remain in
effect through September 30, 2025. For
applications that are submitted on or
after October 1, 2024, the new fee
schedule must be used.
II. Fee Revenue Amount for FY 2025
The base revenue amount for FY 2025
is $51,058,823 prior to adjustments for
inflation, strategic hiring and retention,
capacity planning, operating reserves,
and the additional dollar amount (see
section 744H(b) and (c) of the FD&C
Act).
A. FY 2025 Statutory Fee Revenue
Adjustments for Inflation
BsUFA III specifies that the
$51,058,823 is to be adjusted for
inflation increases for FY 2025 using
two separate adjustments: one for
personnel compensation and benefits
(PC&B) and one for non-PC&B costs (see
section 744H(c)(1) of the FD&C Act).
The component of the inflation
adjustment for payroll costs shall be the
average annual percent change in the
cost of all PC&B paid per full-time
E:\FR\FM\31JYN1.SGM
31JYN1
Agencies
[Federal Register Volume 89, Number 147 (Wednesday, July 31, 2024)]
[Notices]
[Pages 61433-61441]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16883]
[[Page 61433]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-3453]
Medical Device User Fee Rates for Fiscal Year 2025
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the fee
rates and payment procedures for medical device user fees for fiscal
year (FY) 2025. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as
amended by the Medical Device User Fee Amendments of 2022 (MDUFA V),
authorizes FDA to collect user fees for certain medical device
submissions and annual fees both for certain periodic reports and for
establishments subject to registration. This notice establishes the fee
rates for FY 2025, which apply from October 1, 2024, through September
30, 2025, and provides information on how the fees for FY 2025 were
determined, the payment procedures you should follow, and how you may
qualify for reduced small business fees.
FOR FURTHER INFORMATION CONTACT:
For information on Medical Device User Fees: https://www.fda.gov/industry/fda-user-fee-programs/medical-device-user-fee-amendments-mdufa.
For questions relating to the MDUFA Small Business Program, please
visit the Center for Devices and Radiological Health's website: https://www.fda.gov/medical-devices/premarket-submissions/reduced-medical-device-user-fees-small-business-determination-sbd-program.
For questions relating to this notice: Olufunmilayo Ariyo, Office
of Financial Management, Food and Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD 20903, 240-402-4989; or the User Fee
Support Staff at [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
The FD&C Act, as amended by MDUFA V, authorizes FDA to collect user
fees for certain medical device submissions and annual fees both for
certain periodic reports and for establishments subject to
registration. Section 738 of the FD&C Act (21 U.S.C. 379j) establishes
fees for certain medical device applications, submissions, supplements,
notices, and requests (for simplicity, this document refers to these
collectively as ``submissions'' or ``applications''); for periodic
reporting on class III devices; and for the registration of certain
establishments.
Under the FD&C Act, the fee rate for each type of submission is set
at a specified percentage of the standard fee for a premarket
application (a premarket application is a premarket approval
application (PMA), a product development protocol (PDP), or a biologics
license application (BLA)). The FD&C Act specifies the base fee for a
premarket application for each year from FY 2023 through FY 2027; the
base fee for a premarket application received by FDA during FY 2025 is
$445,000. From this starting point, this document establishes FY 2025
fee rates for certain types of submissions, and for periodic reporting,
by applying criteria specified in the FD&C Act. Under statutorily
defined conditions, a qualified applicant may receive a fee waiver or
may pay a lower small business fee (see sections 738(a)(3)(B), 738(d)
and 738(e) of the FD&C Act). For more information on fee waivers,
please see Section IX. Small Business Fee Reductions and Fee Waivers.
The FD&C Act specifies the base fee for establishment registration
for each year from FY 2023 through FY 2027; the base fee for an
establishment registration in FY 2025 is $7,100. Each establishment
that is registered (or is required to register) with the Secretary of
Health and Human Services under section 510 of the FD&C Act (21 U.S.C.
360), because such establishment is engaged in the manufacture,
preparation, propagation, compounding, or processing of a device, is
required to pay the annual fee for establishment registration.
II. Total Revenue Amount for FY 2025
The total revenue amount for FY 2025 is $350,746,400, as set forth
in the statute prior to the inflation adjustment (see section 738(b)(3)
of the FD&C Act). MDUFA V directs FDA to use the yearly total revenue
amount as a starting point to set the standard fee rates for each fee
type. The fee calculations for FY 2025 are described in this document.
Inflation Adjustment
MDUFA specifies that the $350,746,400 is to be adjusted for
inflation increases for FY 2025 using two separate adjustments: one for
payroll costs and one for non-payroll costs (see section 738(c)(2) of
the FD&C Act). The base inflation adjustment for FY 2025 is the sum of
one plus the two separate adjustments and is compounded as specified in
the statute (see section 738(c)(2)(C) and 738(c)(2)(B) of the FD&C
Act).
The component of the inflation adjustment for payroll costs is the
average annual percent change in the cost of all personnel compensation
and benefits (PC&B) paid per full-time equivalent (FTE) position at FDA
for the first 3 of the 4 preceding FYs, multiplied by 0.60, or 60
percent (see section 738(c)(2)(C)(i)(I) of the FD&C Act).
Table 1 summarizes the actual cost and FTE data for the specified
FYs, provides the percent change from the previous fiscal year, and
provides the average percent change over the first 3 of the 4 fiscal
years preceding FY 2025. The 3-year average is 3.8539 percent
(rounded).
Table 1--FDA PC&Bs Each Year and Percent Change
----------------------------------------------------------------------------------------------------------------
FY 2021 FY 2022 FY 2023 3-Year average
----------------------------------------------------------------------------------------------------------------
Total PC&B................................ $3,039,513,000 $3,165,477,000 $3,436,513,000 ..............
Total FTE................................. 18,501 18,474 18,729 ..............
PC&B per FTE.............................. $164,289 $171,348 $183,486 ..............
Percent change from previous year......... 0.1811% 4.2967% 7.0838% 3.8539%
----------------------------------------------------------------------------------------------------------------
The payroll adjustment is 3.8539 percent multiplied by 60 percent,
or 2.3123 percent. The statute specifies that the component of the
inflation adjustment for non-payroll costs for FY 2025 is the average
annual percent change that occurred in the Consumer Price Index (CPI)
for urban consumers (Washington-Arlington-Alexandria, DC-VA-MD-WV; Not
Seasonally Adjusted; All Items; Annual Index) for the first 3 of the
preceding 4 years of available
[[Page 61434]]
data multiplied by 0.40, or 40 percent (see section 738(c)(2)(C)(i)(II)
of the FD&C Act).
Table 2 provides the summary data and the 3-year average percent
change in the specified CPI for the Washington-Arlington-Alexandria
area. These data are published by the Bureau of Labor Statistics and
can be found on their website under series Id CUURS35ASA0 at: https://data.bls.gov/pdq/SurveyOutputServlet?data_tool=dropmap&series_id=CUURS35ASA0,CUUSS35ASA0.
Table 2--Annual and 3-Year Average Percent Change in Washington-Arlington-Alexandria Area CPI
----------------------------------------------------------------------------------------------------------------
2021 2022 2023 3-Year average
----------------------------------------------------------------------------------------------------------------
Annual CPI................................ 277.728 296.117 305.317 ..............
Annual Percent Change..................... 3.9568% 6.6212% 3.1069% ..............
3-Year Average Percent Change in CPI...... ................ ................ ................ 4.5616%
----------------------------------------------------------------------------------------------------------------
The non-payroll adjustment is 4.5616 percent multiplied by 40
percent, or 1.8246 percent. Next, the payroll adjustment (2.3123
percent or 0.023123) is added to the non-payroll adjustment (1.8246
percent or 0.018246), for a total of 4.1369 percent (or 0.041369). To
complete the inflation adjustment, 1 (100 percent or 1.0) is added for
a total base inflation adjustment of 1.041369 for FY 2025. If the base
inflation adjustment for a fiscal year is greater than 1.04, such
adjustment shall be considered to be equal to 1.04 (see section
738(c)(2)(C)(ii)(II) of the FD&C Act). The total base inflation
adjustment for FY 2025 is 1.04.
MDUFA V provides for this inflation adjustment to be compounded for
FY 2023 and each subsequent fiscal year (see section 738(c)(2)(B) of
the FD&C Act). To complete the compounded inflation adjustment for FY
2025, the FY 2024 compounded adjustment (1.079318) is multiplied by the
FY 2025 base inflation adjustment (1.040000) to reach the applicable
inflation adjustment of 1.122491 (rounded) for FY 2025. We then
multiply the total revenue amount for FY 2025 ($350,746,400) by
1.122491, yielding an inflation adjusted total revenue amount of
$393,710,000 (rounded to the nearest thousand dollars).
III. Adjustments to Base Fee Amounts for FY 2025
Under the FD&C Act, all submission fees and the periodic reporting
fee are set as a percent of the standard (full) fee for a premarket
application (see section 738(a)(2)(A) and (b)(1) of the FD&C Act).
A. Inflation Adjustment
MDUFA specifies that the base fees of $445,000 (premarket
application) and $7,100 (establishment registration) are to be adjusted
for FY 2025 using the same methodology as that for the total revenue
inflation adjustment in section II (see section 738I(2)(D)(i) of the
FD&C Act). Multiplying the base fees by the compounded inflation
adjustment of 1.122491 yields inflation adjusted base fees of $499,508
(premarket application) and $7,970 (establishment registration).
B. Further Adjustments To Generate the Inflation-Adjusted Total Revenue
Amount
After the applicable inflation adjustment to fees is done, FDA may
increase, if necessary to achieve the inflation adjusted total revenue
amount, the base fee amounts on a uniform proportionate basis (see
section 738(c)(2)(D)(ii) of the FD&C Act). After this adjustment, if
necessary, FDA may further increase the base establishment registration
fees to generate the inflation-adjusted total revenue amount (see
section 738(c)(3) of the FD&C Act).
For FY 2025, further adjustments were required to meet the
inflation adjusted total revenue amount of $393,710,000. After
increasing base fees, on a uniform proportionate basis, and further
increasing establishment registration fees, this yields inflation
adjusted base fees of $540,783 (premarket application) and $8,716
(establishment registration).
C. MDUFA V Adjustments Solely to Registration Fees
MDUFA V has three new potential adjustments that will not change
the total revenue amount but may impact collections by increasing or
decreasing establishment registration base fees only. These adjustments
are the performance improvement adjustment, the hiring adjustment, and
the operating reserve adjustment.
1. Performance Improvement Adjustment
Beginning with FY 2025, this adjustment allows FDA to collect fees
in addition to the total revenue amount in FYs 2025, 2026, and 2027, if
the Agency meets certain performance goals in FYs 2023, 2024, and 2025.
If applicable, this provision further increases base establishment
registration fee amounts to achieve an increase in total fee
collections equal to the applicable performance improvement adjustment,
which is set forth in the statute (see section 738(c)(4) of the FD& C
Act). FDA met the FY 2023 Pre-Submission Written Feedback goal, which
triggers the performance improvement adjustment for FY 2025.
For FY 2025, the performance improvement adjustment is equal to the
product of the pre-submission amount in section 738(c)(4)(B)(i)(I) of
the FD&C Act, $15,396,600, and the inflation adjustment under section
738(c)(2)(B) of the FD&C Act, 1.122491. See section 738(c)(4)(A)(i) of
the FD&C Act. For FY 2025, the performance improvement adjustment is
$17,282,545.
2. Hiring Adjustment
Beginning with FY 2025, this adjustment provides for the reduction
of base establishment registration fees in FYs 2025, 2026, and 2027, if
specified hiring goals for FYs 2023, 2024, and 2025 are not met by a
certain threshold. The hiring adjustment would serve to decrease the
base establishment registration fee amounts, as necessary, to achieve a
reduction in total fee collections equal to the hiring adjustment
amount, which is set forth in the statute (see section 738(c)(5) of the
FD&C Act).
FDA met the FY 2023 statutory hiring threshold of 123 hires, so
establishment registration fees will not need to be lowered by the
hiring adjustment amount in FY 2025. Since FDA met the FY 2023 Pre-
Submission Written Feedback goal, the FY 2027 statutory hiring goal
will be 83 hires for fiscal year 2025 (see section
738(c)(5)(D)(iii)(II) of the FD&C Act) and the threshold will be 75
hires for fiscal year 2025 (see section 738(c)(5)(B)(iii)(II) of the
FD&C Act).
3. Operating Reserve Adjustment
For FYs 2023 to 2027, the operating reserve adjustment requires FDA
to decrease base establishment registration fees if the amount of
operating reserves
[[Page 61435]]
of carryover user fees exceeds the ``designated amount'', and such
reduction is necessary to provide for not more than such designated
amount of operating reserves of carryover user fees (see section
738(c)(6)(A) of the FD&C Act). In making this calculation for FYs 2023
to 2026, a certain amount is excluded from the designated amount and is
not subject to the decrease (see section 738(c)(6)(C) of the FD&C Act).
For FY 2025, this excluded amount is $77,496,161.
The designated amount is equal to the sum of 13 weeks of operating
reserves of carryover user fees plus 1 month of operating reserves, as
described in 738(c)(8) (see 738(c)(6)(B) of the FD&C Act).
To determine the 13-week operating reserves of carryover user fees
amount, the FY 2025 inflation-adjusted total revenue amount (from
section II), $393,710,000, is added to the inflation-adjusted
performance improvement adjustment amount (from section III.C.1),
$17,282,545, resulting in $410,992,545. This amount is then divided by
52, and then multiplied by 13. The 13-week operating reserve amount for
FY 2025 is $102,748,136.
To determine the 1 month of operating reserves described in section
738(c)(8) of the FD&C Act, the FY 2025 inflation-adjusted total revenue
amount of $393,710,000 is added to the inflation-adjusted performance
improvement adjustment amount of $17,282,545, resulting in
$410,992,545. This amount is then divided by 12. The 1 month of
operating reserves for FY 2025 is $34,249,379.
For FY 2025, the designated amount is equal to the 13-week
operating reserve of $102,748,136 plus the 1 month of operating
reserves of $34,249,379, totaling $136,997,515.
To determine the FY 2024 end-of-year operating reserves of
carryover user fees amount, FDA combined the actual collections and
obligations at the end of the third quarter (June 2024) and added the
forecasted collections and obligations for the fourth quarter of FY
2024 to generate a full year estimate for FY 2024. The estimated end-
of-year FY 2024 operating reserves of carryover user fees is
$50,394,972 (Note, this amount includes the 1-month reserve).
Note that under MDUFA V, for the purposes of calculating the
operating reserve adjustment, this amount does not include user fee
funds considered unappropriated ($26,680,243) or unearned revenue
($62,498,454). In addition, as noted above, for purposes of the
operating reserve adjustment, operating reserves of carryover user fees
do not include the estimated $77,496,161 remaining to spend at the end
of FY 2024 from the total of $118,000,000 intended to support the Total
Product Life Cycle Advisory Program Pilot and Third-Party Review
programs.
Because the estimated end-of-year FY 2024 MDUFA operating reserves
of carryover user fees amount totaling $50,394,972 does not exceed the
FY 2025 designated amount of $136,997,515, FDA will not decrease the
base establishment registration fee amounts for FY 2025 to provide for
not more than such designated amount.
As there is a performance improvement adjustment for FY 2025, but
no hiring adjustment or operating reserve adjustment, establishment
registration fees are increased to achieve an increase in total fee
collections for FY 2025 equal to the performance improvement adjustment
amount of $17,282,545. After so increasing establishment registration
fees only, this yields fees of $540,783 (premarket application) and
$9,280 (establishment registration).
IV. Calculation of Fee Rates
As noted in section II, the total revenue amount after the
applicable inflation adjustment is $393,710,000 (rounded to the nearest
thousand dollar). As noted in section III, the performance improvement
adjustment solely to registration fees for FY 2025 is $17,282,545.
There is no hiring adjustment or operating reserve adjustment for FY
2025.
Table 3A provides fee-paying submission counts, excluding
establishment registration, for the last 3 years and the 3-year
average. Table 3B provides establishment registration fee-paying
submission counts for the most recently completed fiscal year (FY
2023). Historically, FDA has estimated the total number of fee-paying
submission counts it expects to receive during the next fiscal year by
averaging the number of fee-paying submission counts received in the 3
most recently completed fiscal years; for FY 2025 fee-setting, this
would be an average of FY 2021 through FY 2023. FDA received an
abnormally high volume of fee-paying establishment registrations due to
the COVID-19 pandemic in FY 2020 and FY 2021. The surge in fee-paying
establishment registrations has been declining starting in FY 2022,
trending back toward pre-pandemic levels. In an effort to normalize the
projected volume of establishment registration submissions for the FY
2025 fee-setting calculation, and more accurately project the
associated establishment registration revenue, FDA decided to utilize
the number of establishment registration fee-paying submission counts
from FY 2023.
Table 3A--Three-Year Average of Fee-Paying Submissions
[Excluding establishment registration]
----------------------------------------------------------------------------------------------------------------
Application type FY 2021 actual FY 2022 actual FY 2023 actual 3 Yr average
----------------------------------------------------------------------------------------------------------------
Full Fee applications........................... 25 18 31 25
Small Business.............................. 5 3 3 4
Panel-Track Supplements......................... 31 21 22 25
Small Business.............................. 6 1 5 4
De Novo Classifications......................... 16 23 26 22
Small Business.............................. 42 53 68 54
180-Day Supplements............................. 98 93 113 101
Small Business.............................. 34 31 12 26
Real-Time Supplements........................... 150 140 138 143
Small Business.............................. 20 12 28 20
510(k)s......................................... 2,133 2,012 1,943 2,029
Small Business.............................. 1,846 1,757 2,031 1,878
30-Day Notice (Note also includes counts for 135 843 782 825 817
Day Supplements)...............................
Small Business.............................. 77 67 53 66
513(g)(21 U.S.C. 360c(g)) Request for 83 93 82 86
Classification Information.....................
Small Business.............................. 53 58 59 57
[[Page 61436]]
Annual Fee for Periodic Reporting............... 613 620 657 630
Small Business.............................. 84 87 22 64
----------------------------------------------------------------------------------------------------------------
Table 3B--Fiscal Year 2023 Actual Fee-Paying Establishment Registration
Submissions
------------------------------------------------------------------------
FY 2025 estimate for
Application type FY 2023 registrations
------------------------------------------------------------------------
Establishment Registrations..... 30,645 30,645
------------------------------------------------------------------------
The information in tables 3A and 3B is necessary to estimate the
amount of revenue that will be collected based on the fee amounts.
Tables 4A and 4B display the FY 2025 base fees set in statute (column
one) and the inflation adjusted base fees (per calculations in section
III.A.) (column two). Using the inflation adjusted fees, the 3-year
average of fee-paying submissions (excluding establishment
registration), and the fee-paying establishment registration
submissions from FY 2023, collections are projected to total
$361,177,583 which is $32,532,417 lower than the inflation adjusted
total revenue amount (in section II). Accordingly, the next step in the
fee setting process is to increase the base fee amounts on a uniform
proportionate basis to generate the inflation adjusted total revenue
amounts (see 738(c)(2)(D)(ii) of the FD&C Act and table 4A, column
three).
Applying these further adjusted fee rates to the 3-year average of
fee-paying submissions, and the fee-paying establishment registration
submissions from FY 2023 results in estimated total fee collections of
$391,014,947 which is still $2,695,053 lower than the inflation
adjusted total revenue amount (in Section II). The next step in the fee
setting process, after the adjustment in (2)(D) is done, is to increase
the base establishment registration fee amount as necessary for total
fee collections to generate the inflation adjusted total revenue
amount, as adjusted under paragraph (2) (see 738(c)(3) of the FD&C
Act). Accordingly, the base establishment registration fee was
increased by $88 for an establishment registration fee rate of $8,716
(see 738(c)(3) of the FD& C Act and table 4B, column three). The
performance improvement adjustment amount is $17,282,544. Per statute,
the establishment registration fee is further adjusted to account for
the performance improvement adjustment amount. The inflation adjusted
establishment registration fee is increased by $564 for an
establishment registration fee of $9,280. The fees in column three in
table 4A and column four in table 4B are those we are establishing for
FY 2025, which are the standard fees.
Table 4A--Fees Needed To Achieve New FY 2025 Revenue Target
----------------------------------------------------------------------------------------------------------------
Adjusted FY 2025
FY 2025 FY 2025 fees to meet
statutory inflation revenue target 3-Year average FY 2025 revenue
Application type fees (base adjusted (uniform of fee-paying from adjusted
fees) statutory proportionate submissions fees
base fees increase)
----------------------------------------------------------------------------------------------------------------
Full Fee Applications............. $445,000 $499,508 $540,783 25 $13,519,575
Small Business................ 111,250 124,877 135,196 4 540,784
Panel-Track Supplement............ 356,000 399,607 432,626 25 10,815,650
Small Business................ 89,000 99,902 108,157 4 432,628
De Novo Classification Request.... 133,500 149,583 162,235 22 3,569,170
Small Business................ 33,375 37,463 40,559 54 2,190,186
180-Day Supplements............... 66,750 74,926 81,117 101 8,192,817
Small Business................ 16,688 18,732 20,279 26 527,254
Real-Time Supplements............. 31,150 34,966 37,855 143 5,413,265
Small Business................ 7,788 8,741 9,464 20 189,280
510(k)s........................... 20,025 22,478 24,335 2,029 49,375,715
Small Business................ 5,006 5,619 6,084 1,878 11,425,752
30-Day Notice..................... 7,120 7,992 8,653 817 7,069,501
Small Business................ 3,560 3,996 4,326 66 285,516
513(g) Request for Classification 6,008 6,743 7,301 86 627,886
Information......................
Small Business................ 3,004 3,372 3,650 57 208,050
Annual Fee for Periodic Reporting. 15,575 17,483 18,927 630 11,924,010
Small Business................ 3,894 4,371 4,732 64 302,848
-----------------------------------------------------------------------------
Total..................... ............ ........... ................ .............. 126,609,887
----------------------------------------------------------------------------------------------------------------
[[Page 61437]]
Table 4B--Fees Needed To Achieve New FY 2025 Revenue Target Plus/Minus Adjustments
--------------------------------------------------------------------------------------------------------------------------------------------------------
Adjusted FY 2025 fees to
meet inflation adjusted Adjusted FY
FY 2025 total revenue amount 2025 fees to
FY 2025 inflation (uniform proportionate meet inflation FY 2023 fee- FY 2025 revenue
Application type statutory fees adjusted increase + further adjusted total paying from adjusted
(base fees) statutory adjustment to revenue +/- submissions fees
base fees establishment adjustments
registrations)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Establishment Registrations................. $7,100 $7,970 $8,716 $9,280 30,645 $267,101,820
--------------------------------------------------------------------------------------------------------------------------------------------------------
The standard fee (adjusted base amount) for a premarket
application, including a BLA, and for a premarket report and a BLA
efficacy supplement, is $540,783 for FY 2025. The fees set by reference
to the standard fee for a premarket application are:
For a panel-track supplement, 80 percent of the standard fee
For a de novo classification request, 30 percent of the
standard fee
For a 180-day supplement, 15 percent of the standard fee
For a real-time supplement, 7 percent of the standard fee
For an annual fee for periodic reporting concerning a class
III device, 3.5 percent of the standard fee
For a 510(k) premarket notification, 4.5 percent of the
standard fee
For a 30-day notice, 1.6 percent of the standard fee
For a 513(g) request for classification information, 1.35
percent of the standard fee
For all submissions other than a 30-day notice and a 513(g) request
for classification information, the small business fee is 25 percent of
the standard (full) fee for the submission (see section 738(d)(2)(C)
and (e)(2)(C) of the FD&C Act). For a 30-day notice and a 513(g)
request for classification information, the small business fee is 50
percent of the standard (full) fee for the submission (see section
738(d)(2)(C) of the FD&C Act).
The annual fee for establishment registration, after adjustments,
is set at $9,280 for FY 2025. For FY 2025, there is no small business
waiver for the annual establishment registration fee; all
establishments pay the same fee.
For more information on reduced fees and waivers for small
businesses, please see Section IX. Small Business Fee Reductions and
Fee Waivers.
Table 5 summarizes the FY 2025 rates for all medical device fees.
Table 5--Medical Device Fees for FY 2025
----------------------------------------------------------------------------------------------------------------
Standard fee (as a percent of
Application fee type the standard fee for a premarket FY 2025 FY 2025 small
application) standard fee business fee
----------------------------------------------------------------------------------------------------------------
Premarket application (a PMA submitted under Base fee specified in statute... $540,783 $135,196
section 515(c)(1) of the FD&C Act (21 U.S.C.
360e(c)(1)), a PDP submitted under section
515(f) of the FD&C Act, or a BLA submitted
under section 351 of the Public Health
Service Act (the PHS Act) (42 U.S.C. 262)).
Premarket report (submitted under section 100%............................ 540,783 135,196
515(c)(2) of the FD&C Act).
Efficacy supplement (to an approved BLA under 100%............................ 540,783 135,196
section 351 of the PHS Act).
Panel-track supplement....................... 80%............................. 432,626 108,157
De novo classification request............... 30%............................. 162,235 40,559
180-day supplement........................... 15%............................. 81,117 20,279
Real-time supplement......................... 7%.............................. 37,855 9,464
510(k) premarket notification submission..... 4.5%............................ 24,335 6,084
30-day notice................................ 1.60%........................... 8,653 4,326
513(g) request for classification information 1.35%........................... 7,301 3,650
Annual Fee Type.............................. ................................ .............. ...............
Annual fee for periodic reporting on a class 3.50%........................... 18,927 4,732
III device.
Annual establishment registration fee (to be Base fee specified in statute... 9,280 9,280
paid by the establishment engaged in the
manufacture, preparation, propagation,
compounding, or processing of a device, as
defined by 21 U.S.C. 379i(14)).
----------------------------------------------------------------------------------------------------------------
V. How To Qualify as a Small Business for Purposes of Medical Device
Fees
If your business, including your affiliates, has gross receipts or
sales of no more than $100 million for the most recent tax year, you
may qualify for reduced small business fees. If your business,
including your affiliates, has gross sales or receipts of no more than
$30 million, you may also qualify for a waiver of the fee for your
first premarket application (i.e., PMA, PDP, or BLA) or premarket
report. If you want to pay the small business fee rate for a submission
or you want to receive a waiver of the fee for your first premarket
application or premarket report, you must submit the materials showing
you qualify as a small business at least 60 days before you send your
submission to FDA. For more information on fee waivers or reductions,
please see Section IX. Small Business Fee Reductions and Fee Waivers.
Please note that the establishment registration fee is not eligible
for a reduced small business fee. For FY 2025, there is no small
business waiver for the annual establishment registration fee. As a
result, if the establishment registration fee is the only medical
device user fee that you will pay in FY 2025, you should not submit a
Small Business Certification Request. FDA will review your information
and determine whether you qualify as a small business eligible for the
reduced fee and/or fee waiver. If you make a submission before FDA
finds that you qualify as a small business, you must pay the standard
(full) fee for that submission.
If your business qualified as a small business for FY 2024, your
status as a small business will expire at the close of business on
September 30, 2024. You must re-qualify for FY 2025 in order to pay
small business fees during FY 2025.
[[Page 61438]]
A. Domestic (U.S.) Businesses
If you are a domestic (U.S.) business and wish to qualify as a
small business for FY 2025, submit the following to FDA:
1. A completed MDUFA Small Business Certification Request for a
Business Headquartered in the United States (Form FDA 3602). Form FDA
3602 is provided in the FDA Forms database: https://www.fda.gov/about-fda/reports-manuals-forms/forms.
2. A signed copy of your Federal (U.S.) Income Tax Return for the
most recent tax year. The most recent tax year will be 2024, except:
If you submit your MDUFA Small Business Certification
Request for FY 2025 before April 15, 2025, and you have not yet filed
your return for 2024, you may use tax year 2023.
If you submit your MDUFA Small Business Certification
Request for FY 2025 on or after April 15, 2025, and have not yet filed
your 2024 return because you obtained an extension, you may submit your
most recent return filed prior to the extension.
3. For each of your affiliates, either:
If the affiliate is a domestic (U.S.) business, a signed
copy of the affiliate's Federal (U.S.) Income Tax Return for the most
recent tax year, or
If the affiliate is a foreign business and cannot submit a
Federal (U.S.) Income Tax Return, a National Taxing Authority
Certification completed by, and bearing the official seal of, the
National Taxing Authority, if extant, of the country in which the firm
is headquartered. The National Taxing Authority is the foreign
equivalent of the U.S. Internal Revenue Service. This certification
must show the amount of gross receipts or sales for the most recent tax
year, in both U.S. dollars and the local currency of the country, the
exchange rate used in converting the local currency to U.S. dollars,
and the dates of the gross receipts or sales collected. The business
must also submit a statement signed by the head of the business's firm
or by its chief financial officer that the business has submitted
certifications for all of its affiliates, identifying the name of each
affiliate, or that the business has no affiliates.
If your affiliate is headquartered in a country without a
National Taxing Authority, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
4. Once you have completed and signed your Form FDA 3602, submit
your form and your supporting documentation (copies of the Federal
(U.S.) income tax returns), using the instructions which are available
at the following website: https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm577696.htm.
If you need assistance, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
B. Foreign Businesses
If you are a foreign business, and wish to qualify as a small
business for FY 2025, submit the following:
1. A completed MDUFA Foreign Small Business Certification Request
for a Business Headquartered Outside the United States (Form FDA
3602A). Form FDA 3602A is provided in the FDA Forms database: https://www.fda.gov/about-fda/reports-manuals-forms/forms.
2. A National Taxing Authority Certification, completed by, and
bearing the official seal of, the National Taxing Authority, if extant,
of the country in which the firm is headquartered. This certification
must show the amount of gross receipts or sales for the most recent tax
year, in both U.S. dollars and the local currency of the country, the
exchange rate used in converting the local currency to U.S. dollars,
and the dates of the gross receipts or sales collected.
If your firm is headquartered in a country without a National
Taxing Authority, please contact the Division of Industry and Consumer
Education at 800-638-2041 or 301-796-7100 or email at [email protected].
3. For each of your affiliates, either:
If the affiliate is a domestic (U.S.) business, a signed
copy of the affiliate's Federal (U.S.) Income Tax Return for the most
recent tax year (2023 or later), or
If the affiliate is a foreign business and cannot submit a
Federal (U.S.) Income Tax Return, a National Taxing Authority
Certification completed by, and bearing the official seal of, the
National Taxing Authority, if extant, of the country in which the firm
is headquartered. The National Taxing Authority is the foreign
equivalent of the U.S. Internal Revenue Service. This certification
must show the amount of gross receipts or sales for the most recent tax
year, in both U.S. dollars and the local currency of the country, the
exchange rate used in converting the local currency to U.S. dollars,
and the dates for the gross receipts or sales collected. The business
must also submit a statement signed by the head of the business's firm
or by its chief financial officer that the applicant has submitted
certifications for all of its affiliates, identifying the name of each
affiliate, or that the business has no affiliates.
If your affiliate is headquartered in a country without a
National Taxing Authority, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
4. Once you have completed and signed your Form FDA 3602A, submit
your form and your supporting documentation, including the following,
using the instructions which are available at the following website:
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm577696.htm.
A copy of the most recent Federal (U.S.) income tax return
for each of your affiliates headquartered in the U.S. and
A copy of an MDUFA Foreign Small Business Certification
Request for each of your foreign affiliates.
If you need assistance, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
VI. Procedures for Paying Application Fees
If your application or submission is subject to a fee and your
payment is received by FDA between October 1, 2024, and September 30,
2025, you must pay the fee in effect for FY 2025. To avoid delay in the
review of your application, you should pay the application fee at the
time you submit your application to FDA. The later of the date that the
application is received in the reviewing center's document room or the
date the U.S. Treasury recognizes the payment determines whether the
fee rates for FY 2024 or FY 2025 apply. FDA must receive the correct
fee at the time that an application is submitted, or the application
will not be accepted for filing or review.
FDA requests that you follow the steps below before submitting a
medical device application subject to a fee to ensure that FDA links
the fee with the correct application. (Note: Do not send your user fee
check to FDA with the application.)
A. Secure a Payment Identification Number (PIN) and Medical Device User
Fee Cover Sheet From FDA Before Submitting Either the Application or
the Payment
Log into the User Fee System at: https://userfees.fda.gov/OA_HTML/mdufmaCAcdLogin.jsp. Complete the Medical Device User Fee cover sheet.
Be sure you choose the correct application
[[Page 61439]]
submission date range. (Two choices will be offered until October 1,
2024. One choice is for applications and fees that will be received on
or before September 30, 2024, which are subject to FY 2024 fee rates. A
second choice is for applications and fees received on or after October
1, 2024, which are subject to FY 2025 fee rates.) After completing data
entry, print a copy of the Medical Device User Fee cover sheet and note
the unique PIN located in the upper right-hand corner of the printed
cover sheet.
B. Electronically Transmit a Copy of the Printed Cover Sheet With the
PIN
When you are satisfied that the data on the cover sheet is
accurate, electronically transmit that data to FDA according to
instructions on the screen. Applicants are required to set up a user
account and password to assure data security in the creation and
electronic submission of cover sheets.
C. Submit Payment for the Completed Medical Device User Fee Cover Sheet
1. The preferred payment method is online using electronic check
(Automated Clearing House (ACH) also known as eCheck) or credit card
(Discover, VISA, MasterCard, American Express). FDA has partnered with
the U.S. Department of the Treasury to utilize Pay.gov, a web-based
payment system, for online electronic payment. You may make a payment
via electronic check or credit card after submitting your cover sheet.
Secure electronic payments can be submitted using the User Fees Payment
Portal at https://userfees.fda.gov/pay. Note: Only full payments are
accepted. No partial payments can be made online. Once you search for
your invoice, select ``Pay Now'' to be redirected to Pay.gov.
Electronic payment options are based on the balance due. Payment by
credit card is available for balances that are less than $25,000. If
the balance exceeds this amount, only the ACH option is available.
Payments must be made using U.S bank accounts as well as U.S. credit
cards.
2. If paying with a paper check:
All paper checks must be in U.S. currency from a U.S. bank
and made payable to the Food and Drug Administration. If needed, FDA's
tax identification number is 53-0196965.
Please write your application's unique PIN (from the upper
right-hand corner of your completed Medical Device User Fee cover
sheet) on your check.
Mail the paper check and a copy of the completed cover
sheet to: Food and Drug Administration, P.O. Box 979033, St. Louis, MO
63197-9000.
If you prefer to send a check by a courier, the courier may deliver
the check to: U.S. Bank, Attn: Government Lockbox 979033, 3180 Rider
Trail S, Earth City, MO 63045. (Note: This U.S. Bank address is for
courier delivery only. If you have any questions concerning courier
delivery contact U.S. Bank at 800-495-4981. This telephone number is
only for questions about courier delivery).
3. If paying with a wire transfer:
Please include your application's unique PIN (from the
upper right-hand corner of your completed Medical Device User Fee cover
sheet) in your wire transfer. Without the PIN, your payment may not be
applied to your cover sheet and review of your application may be
delayed.
The originating financial institution may charge a wire
transfer fee. If the financial institution charges a wire transfer fee
it is required that you add that amount to the payment to ensure that
the invoice is paid in full.
Use the following account information when sending a wire transfer:
U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York,
NY 10045, Acct. No. 75060099, Routing No. 021030004, SWIFT: FRNYUS33.
FDA records the official application receipt date as the later of
the following: (1) the date the application was received by the FDA
Document Control Center for the reviewing Center or (2) the date the
U.S. Treasury recognizes the payment.
D. Submit Your Application to FDA With a Copy of the Completed Medical
Device User Fee Cover Sheet
Please submit your application and a copy of the completed Medical
Device User Fee cover sheet to the address located at https://www.fda.gov/cdrhsubmissionaddress.
VII. Procedures for Paying the Annual Fee for Periodic Reporting
You will be invoiced at the end of the quarter in which your PMA
Periodic Report is due. Invoices will be sent based on the details
included on your PMA file. You are responsible for ensuring FDA has
your current billing information, and you may update your contact
information for the PMA by submitting an amendment to the pending PMA
or a supplement to the approved PMA.
1. The preferred payment method is online using electronic check
(ACH also known as eCheck) or credit card (Discover, VISA, MasterCard,
American Express). Secure electronic payments can be submitted using
the User Fees Payment Portal at https://userfees.fda.gov/pay (Note:
Only full payments are accepted. No partial payments can be made
online). Once you search for your invoice, select ``Pay Now'' to be
redirected to Pay.gov. Note that electronic payment options are based
on the balance due. Payment by credit card is available for balances
that are less than $25,000. If the balance exceeds this amount, only
the ACH option is available. Payments must be made using U.S. bank
accounts as well as U.S. credit cards.
2. If paying with a paper check: The check must be in U.S. currency
from a U.S. bank and made payable to the Food and Drug Administration.
If needed, FDA's tax identification number is 53-0196965.
Please write your invoice number on the check.
Mail the paper check and a copy of the invoice to: Food
and Drug Administration, P.O. Box 979033, St. Louis, MO 63197-9000.
To send a check by a courier, the courier must deliver the check
and printed copy of the cover sheet to U.S. Bank, Attn: Government
Lockbox 979033, 3180 Rider Trail S, Earth City, MO 63045. (Note: This
U.S. Bank address is for courier delivery only. If you have any
questions concerning courier delivery, contact U.S. Bank at 800-495-
4981. This telephone number is only for questions about courier
delivery).
3. When paying by a wire transfer, it is required that the invoice
number is included; without the invoice number the payment may not be
applied. If the payment amount is not applied, the invoice amount would
be referred to collections. The originating financial institution may
charge a wire transfer fee. If the financial institution charges a wire
transfer fee, it is required that you add that amount to the payment to
ensure that the invoice is paid in full.
Use the following account information when sending a wire transfer:
U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York,
NY 10045, Acct. No. 75060099, Routing No. 021030004, SWIFT: FRNYUS33.
VIII. Procedures for Paying Annual Establishment Registration Fees
To pay the annual establishment registration fee, firms must access
the Device Facility User Fee (DFUF) website at https://userfees.fda.gov/OA_HTML/furls.jsp. (FDA has verified the website
address, but FDA is not responsible for any subsequent changes to the
website
[[Page 61440]]
address after this document publishes in the Federal Register.) Create
a DFUF order and you will be issued a PIN when you place your order.
After payment has been processed, you will be issued a payment
confirmation number (PCN). You will not be able to register your
establishment if you do not have a PIN and a PCN. An establishment
required to pay an annual establishment registration fee is not legally
registered in FY 2025 until it has completed the steps below to
register and pay any applicable fee (see section 738(f)(2) of the FD&C
Act).
Companies that do not manufacture any product other than a licensed
biologic are required to register in the Blood Establishment
Registration (BER) system. FDA's Center for Biologics Evaluation and
Research (CBER) will send establishment registration fee invoices
annually to these companies.
A. Submit a DFUF Order With a PIN From FDA Before Registering or
Submitting Payment
To submit a DFUF Order, you must create or have previously created
a user account and password for the user fee website listed previously
in this section. After creating a username and password, log into the
Establishment Registration User Fee FY 2025 store. Complete the DFUF
order by entering the number of establishments you are registering that
require payment. When you are satisfied that the information in the
order is accurate, electronically transmit that data to FDA according
to instructions on the screen. Print a copy of the final DFUF order and
note the unique PIN located in the upper right-hand corner of the
printed order.
B. Pay for Your DFUF Order
Unless paying by U.S. credit card, all payments must be in U.S.
currency and drawn on a U.S. bank.
1. If paying by credit card or electronic check (ACH or eCheck):
The DFUF order will include payment information, including details on
how you can pay online using a credit card or electronic check. Follow
the instructions provided to make an electronic payment.
2. If paying with a paper check: The check must be in U.S. currency
and drawn on a U.S. bank, and mailed to: Food and Drug Administration,
P.O. Box 979033, St. Louis, MO 63197-9000.
If a check is sent by a courier that requests a street address, the
courier can deliver the check to: U.S. Bank, Attn: Government Lockbox
979033, 3180 Rider Trail S, Earth City, MO 63045. (Note: This U.S. Bank
address is for courier delivery only. If you have any questions
concerning courier delivery, contact U.S. Bank at 800-495-4981. This
telephone number is only for questions about courier delivery.)
Please make sure that both of the following are written on your
check: (1) the FDA post office box number (P.O. Box 979033) and (2) the
PIN that is printed on your order. Include a copy of your printed order
when you mail your check.
3. If paying with a wire transfer: Wire transfers may also be used
to pay annual establishment registration fees. To send a wire transfer,
please read and comply with the following information:
Include your order's unique PIN (in the upper right-hand corner of
your completed DFUF order) in your wire transfer. Without the PIN, your
payment may not be applied to your facility and your registration may
be delayed.
The originating financial institution may charge a wire transfer
fee. If the financial institution charges a wire transfer fee, it is
required that you add that amount to the payment to ensure that the
invoice is paid in full. Use the following account information when
sending a wire transfer: U.S. Dept. of the Treasury, TREAS NYC, 33
Liberty St., New York, NY 10045, Acct. No. 75060099, Routing No.
021030004, SWIFT: FRNYUS33. If needed, FDA's tax identification number
is 53-0196965.
C. Complete the Information Online To Update Your Establishment's
Annual Registration for FY 2025, or To Register a New Establishment for
FY 2025
Go to the Center for Devices and Radiological Health's website at
https://www.fda.gov/medical-devices/how-study-and-market-your-device/device-registration-and-listing and click the ``Access Electronic
Registration'' link on the left side of the page. This opens a new page
with important information about the FDA Unified Registration and
Listing System (FURLS). After reading this information, click on the
``Access Electronic Registration'' link in the middle of the page. This
link takes you to an FDA Industry Systems page with tutorials that
demonstrate how to create a new FURLS user account if your
establishment did not create an account in FY 2024. Manufacturers of
licensed biologics should register in the electronic Blood
Establishment Registration (eBER) system at https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-establishment-registration.
Enter your existing account ID and password to log into FURLS. From
the FURLS/FDA Industry Systems menu, click on the Device Registration
and Listing Module (DRLM) of FURLS button. New establishments will need
to register, and existing establishments will update their annual
registration using choices on the DRLM menu. When you choose to
register or update your annual registration, the system will prompt you
through the entry of information about your establishment and your
devices. If you have any problems with this process, email:
[email protected] or call 301-796-7400 for assistance. (Note: This
email address and this telephone number are for assistance with
establishment registration only; they are not to be used for questions
related to other aspects of medical device user fees.) Problems with
the eBER system should be directed to https://www.accessdata.fda.gov/scripts/email/cber/bldregcontact.cfm or call 240-402-8360.
D. Enter Your DFUF Order PIN and PCN
After completing your annual or initial registration and device
listing, you will be prompted to enter your DFUF order PIN and PCN,
when applicable. This process does not apply to establishments engaged
only in the manufacture, preparation, propagation, compounding, or
processing of licensed biologic devices. CBER will send invoices for
payment of the establishment registration fee to such establishments.
IX. Small Business Fee Reductions and Fee Waivers
To qualify for reduced fees for small businesses or a small
business fee waiver, please see the requirements for qualification
provided in Section V. How To Qualify as a Small Business for Purposes
of Medical Device Fees. The applicant should submit a Small Business
Certification Request and the supporting materials showing you qualify
as a small business at least 60 days before you send your submission to
FDA. FDA will review your information and determine whether you qualify
as a small business eligible for the reduced fee and/or fee waiver. If
you make a submission before FDA finds that you qualify as a small
business, you must pay the standard (full) fee for that submission.
If you need assistance, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
A. Premarket Approval Fee Reduction or Waiver
A small business applicant may request to pay a reduced rate for
[[Page 61441]]
premarket approval fees. An applicant may also request a fee waiver for
their first premarket application or premarket report (section 738(d)
of the FD&C Act).
B. Premarket Notification Submission Fee Reduction
A small business applicant may request to pay a reduced rate for a
premarket notification submission.
C. Annual Establishment Registration Fee Waiver
For FY 2025, there is no small business waiver for the annual
establishment registration fee; all establishments pay the same fee.
X. Refunds
To qualify for consideration for a refund, a person shall submit to
FDA a written request for a refund not later than 180 days after such
fee is due. FDA has discretion to refund a fee or a portion of the fee.
A determination by FDA concerning a refund shall not be reviewable. For
more information on qualifying and submitting a refund, see section
738(a)(2)(D) of the FD&C Act.
Dated: July 26, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-16883 Filed 7-30-24; 8:45 am]
BILLING CODE 4164-01-P